Drug:
Reaction: NO ADVERSE EVENT
20250101 - 20251231
No. 601 - 700
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 601 | 25099968 |
US |
85 | |
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 602 | 25100139 |
US |
55 | 2 |
Product dose omission issue, No adverse event, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 603 | 25100243 |
US |
53 | |
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 604 | 25100250 |
US |
44 | |
Drug dose omission by device, Wrong technique in product usage process, Device deposit issue, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, MONTELUKAST, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, IPRATROPIUM BROMIDE, |
||||
| 605 | 25100381 |
US |
14 | 2 |
Off label use, No adverse event, |
||||
TOCILIZUMAB, TOCILIZUMAB, |
||||
| 606 | 25100535 |
US |
||
Device malfunction, No adverse event, |
||||
PEGFILGRASTIM-CBQV, |
||||
| 607 | 25100562 |
US |
||
Device malfunction, No adverse event, |
||||
PEGFILGRASTIM-CBQV, |
||||
| 608 | 25100585 |
US |
74 | |
Drug dose omission by device, Wrong technique in product usage process, Product use in unapproved indication, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 609 | 25100819 |
US |
2 | |
No adverse event, Pregnancy, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 610 | 25100823 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
| 611 | 25101003 |
US |
2 | |
No adverse event, Pregnancy, |
||||
VEDOLIZUMAB, |
||||
| 612 | 25101110 |
US |
2 | |
No adverse event, Pregnancy, |
||||
VEDOLIZUMAB, |
||||
| 613 | 25101219 |
US |
||
Device malfunction, No adverse event, |
||||
PEGFILGRASTIM-CBQV, |
||||
| 614 | 25101709 |
HR |
84 | 2 |
Suicide attempt, No adverse event, |
||||
AMLODIPINE, |
||||
| 615 | 25101866 |
US |
2 | |
Incorrect route of product administration, No adverse event, |
||||
DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM, |
||||
| 616 | 25101907 |
US |
||
Drug ineffective, Product odour abnormal, No adverse event, |
||||
DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM, |
||||
| 617 | 25102036 |
US |
2 | |
Product dose omission issue, Liquid product physical issue, No adverse event, |
||||
SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, |
||||
| 618 | 25102250 |
JP |
||
Death, No adverse event, |
||||
IPILIMUMAB, NIVOLUMAB, |
||||
| 619 | 25102273 |
US |
28 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 620 | 25102344 |
US |
45 | 1 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 621 | 25092219 |
US |
2 | |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 622 | 25092240 |
US |
2 | |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 623 | 25092243 |
US |
1 | |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, |
||||
| 624 | 25092252 |
US |
||
Exposure during pregnancy, No adverse event, |
||||
| 625 | 25092253 |
US |
||
Exposure during pregnancy, No adverse event, |
||||
RALTEGRAVIR, MARAVIROC, |
||||
| 626 | 25092283 |
US |
45 | 2 |
Product dose omission issue, Syringe issue, No adverse event, |
||||
OMALIZUMAB, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, CETIRIZINE HYDROCHLORIDE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 627 | 25092378 |
US |
37 | 1 |
No adverse event, Overdose, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 628 | 25092379 |
US |
1 | |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 629 | 25092380 |
US |
41 | 2 |
Product use issue, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 630 | 25092457 |
US |
49 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 631 | 25092635 |
US |
||
Off label use, No adverse event, |
||||
EMICIZUMAB, |
||||
| 632 | 25092660 |
US |
54 | 2 |
No adverse event, Off label use, |
||||
OMALIZUMAB, |
||||
| 633 | 25092847 |
US |
2 | |
Wrong technique in product usage process, No adverse event, |
||||
SITAGLIPTIN, |
||||
| 634 | 25092880 |
US |
||
No adverse event, Device issue, Syringe issue, |
||||
AVACINCAPTAD PEGOL, AVACINCAPTAD PEGOL, |
||||
| 635 | 25093098 |
US |
81 | 1 |
Off label use, No adverse event, |
||||
TOCILIZUMAB, TOCILIZUMAB, |
||||
| 636 | 25093117 |
US |
||
Accidental exposure to product, No adverse event, |
||||
IOHEXOL, |
||||
| 637 | 25093529 |
US |
57 | 2 |
Off label use, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 638 | 25093569 |
US |
61 | |
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 639 | 25093638 |
US |
||
Intercepted product storage error, No adverse event, |
||||
OMALIZUMAB, |
||||
| 640 | 25093643 |
US |
68 | |
Wrong technique in device usage process, Incorrect dose administered by device, Wrong technique in product usage process, Product use in unapproved indication, Device mechanical issue, Device malfunction, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 641 | 25093663 |
US |
||
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 642 | 25093706 |
US |
||
Wrong technique in device usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 643 | 25093795 |
US |
2 | |
No adverse event, Product availability issue, |
||||
LISDEXAMFETAMINE DIMESYLATE, |
||||
| 644 | 25093908 |
US |
68 | |
Product preparation error, Device delivery system issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 645 | 25093948 |
US |
8 | 1 |
Off label use, No adverse event, |
||||
TOCILIZUMAB, TOCILIZUMAB, |
||||
| 646 | 25093949 |
US |
54 | 1 |
Product dose omission issue, Wrong technique in product usage process, No adverse event, Device defective, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, RISANKIZUMAB-RZAA, |
||||
| 647 | 25094046 |
US |
||
Off label use, No adverse event, |
||||
RITUXIMAB, |
||||
| 648 | 25094186 |
US |
||
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 649 | 25094187 |
US |
||
Expired device used, Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 650 | 25094388 |
US |
66 | |
Product prescribing issue, No adverse event, |
||||
BUDESONIDE, |
||||
| 651 | 25094401 |
US |
2 | |
Off label use, No adverse event, |
||||
SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, |
||||
| 652 | 25094518 |
US |
1 | |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 653 | 25094683 |
US |
||
Drug dose omission by device, Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 654 | 25094689 |
US |
63 | |
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, LOSARTAN, AMLODIPINE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, FOLIC ACID, |
||||
| 655 | 25094826 |
US |
1 | |
Incorrect route of product administration, No adverse event, |
||||
QUIZARTINIB, |
||||
| 656 | 25094952 |
US |
||
Wrong technique in product usage process, No adverse event, |
||||
TIOTROPIUM BROMIDE, |
||||
| 657 | 25094960 |
US |
1 | |
Drug ineffective, No adverse event, |
||||
RITUXIMAB, POLATUZUMAB VEDOTIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, PREDNISONE, |
||||
| 658 | 25094982 |
US |
||
No adverse event, |
||||
BIMATOPROST, |
||||
| 659 | 25095004 |
US |
30 | |
Wrong technique in product usage process, Device deposit issue, Device malfunction, No adverse event, |
||||
ALBUTEROL SULFATE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 660 | 25095465 |
US |
||
Device malfunction, No adverse event, |
||||
PEGFILGRASTIM-CBQV, |
||||
| 661 | 25095482 |
US |
||
Device malfunction, No adverse event, |
||||
PEGFILGRASTIM-CBQV, |
||||
| 662 | 25095600 |
US |
||
Drug ineffective, No adverse event, |
||||
| 663 | 25095606 |
US |
||
Drug ineffective, No adverse event, |
||||
| 664 | 25095614 |
US |
1 | |
No adverse event, |
||||
DALFAMPRIDINE, DIMETHYL FUMARATE, DIMETHYL FUMARATE, DIMETHYL FUMARATE, |
||||
| 665 | 25095680 |
US |
1 | |
No adverse event, |
||||
DALFAMPRIDINE, |
||||
| 666 | 25095776 |
US |
1 | 2 |
Poor quality product administered, Product contamination physical, No adverse event, |
||||
RISDIPLAM, |
||||
| 667 | 25095895 |
US |
2 | |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, |
||||
| 668 | 25096486 |
US |
39 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 669 | 25096504 |
US |
||
No adverse event, Product storage error, |
||||
VEDOLIZUMAB, |
||||
| 670 | 25096876 |
US |
||
Off label use, No adverse event, |
||||
TENECTEPLASE, |
||||
| 671 | 25096928 |
US |
||
Product dose omission issue, No adverse event, |
||||
PEMBROLIZUMAB, |
||||
| 672 | 25097120 |
US |
68 | 2 |
Off label use, No adverse event, |
||||
RITUXIMAB, |
||||
| 673 | 25086783 |
US |
77 | 2 |
Off label use, No adverse event, |
||||
ENTRECTINIB, |
||||
| 674 | 25086911 |
US |
||
Device malfunction, No adverse event, |
||||
PEGFILGRASTIM-CBQV, |
||||
| 675 | 25086919 |
US |
||
Off label use, No adverse event, |
||||
FARICIMAB, |
||||
| 676 | 25086920 |
US |
26 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 677 | 25086934 |
US |
||
Device malfunction, No adverse event, |
||||
PEGFILGRASTIM-CBQV, |
||||
| 678 | 25087004 |
US |
1 | |
Off label use, No adverse event, |
||||
EMICIZUMAB, |
||||
| 679 | 25087310 |
US |
1 | |
Device defective, Product physical issue, No adverse event, |
||||
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE OPHTHALMIC, |
||||
| 680 | 25087311 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE OPHTHALMIC, |
||||
| 681 | 25087312 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE OPHTHALMIC, |
||||
| 682 | 25087313 |
US |
1 | |
Product delivery mechanism issue, Device leakage, No adverse event, |
||||
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE OPHTHALMIC, |
||||
| 683 | 25087316 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE OPHTHALMIC, OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE OPHTHALMIC, |
||||
| 684 | 25087318 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE OPHTHALMIC, |
||||
| 685 | 25087319 |
US |
1 | |
Device defective, No adverse event, |
||||
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE OPHTHALMIC, |
||||
| 686 | 25087320 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE OPHTHALMIC, |
||||
| 687 | 25087321 |
US |
1 | |
Device leakage, No adverse event, |
||||
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE OPHTHALMIC, |
||||
| 688 | 25087322 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE OPHTHALMIC, |
||||
| 689 | 25087371 |
US |
||
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 690 | 25087389 |
US |
60 | |
Drug dose omission by device, Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, |
||||
| 691 | 25087392 |
US |
29 | 2 |
Product communication issue, Product dose omission issue, No adverse event, |
||||
OMALIZUMAB, |
||||
| 692 | 25087495 |
US |
25 | |
Drug dose omission by device, Device delivery system issue, Off label use, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 693 | 25087496 |
US |
13 | |
Product storage error, No adverse event, |
||||
CEFDINIR, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, |
||||
| 694 | 25087566 |
US |
32 | |
Product storage error, No adverse event, |
||||
RIFAMPIN, |
||||
| 695 | 25087576 |
US |
||
Accidental exposure to product, No adverse event, |
||||
IODIXANOL, |
||||
| 696 | 25087629 |
US |
65 | 1 |
Off label use, No adverse event, |
||||
RITUXIMAB, RITUXIMAB, |
||||
| 697 | 25087797 |
US |
7 | 1 |
Off label use, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 698 | 25087860 |
US |
1 | |
Off label use, Off label use, Drug ineffective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 699 | 25087926 |
US |
67 | |
Wrong technique in product usage process, Device delivery system issue, Device deposit issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 700 | 25087935 |
US |
14 | |
Wrong technique in product usage process, Drug dose omission by device, No adverse event, |
||||
ALBUTEROL SULFATE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28